Stocks · News reference

Quoin Pharmaceuticals Said Key Secondary Endpoint Of Global Impression of Change Also Achieved Statistical Significance At Week 12

Aug 28, 2026, 10:12 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 28, 2026, 5:59 PMBenzinga Newsdesk
QNRX shares are trading higher after the company announced interim Phase 2/3 results showing QRX003 met the primary and key secondary endpoints with statistical significance, along with itch reduction and no serious adverse events.
QNRX
SEC EDGARAug 28, 2026, 2:31 PMSEC EDGAR
8-K filing — Quoin Pharmaceuticals, Ltd. (QNRX)
Filed: 2026-08-28 AccNo: 0001104659-26-102917 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
QNRX
BenzingaAug 28, 2026, 2:09 PMAvi Kapoor
Dow Gains 100 Points; Chicago PMI Falls In August
US stocks up, Dow gains 100 points, S&P 500 and NASDAQ also rise. Communication services up 1.1%, technology down 0.3%. Chicago Business Barometer dips.
AEHL BTAI CYAB FNGR KXIN
BenzingaAug 28, 2026, 1:40 PMHenry Khederian
Quoin Pharmaceuticals Stock Surges Friday: What's Happening?
Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial results and a major institutional financing.
QNRX